ARTICLE | Clinical News
Alkermes submits NDA to FDA for Biogen-partnered MS candidate
January 4, 2019 1:19 AM UTC
Alkermes plc (NASDAQ:ALKS) submitted an NDA to FDA under under section 505(b)(2) of the Food, Drug and Cosmetic Act seeking approval of diroximel fumarate (BIIB098) to treat relapsing forms of multiple sclerosis. Alkermes' partner Biogen Inc. (NASDAQ:BIIB) intends to market the product under the brand name Vumerity...